nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—CHRM1—epilepsy syndrome	0.327	0.551	CbGaD
Flavoxate—CHRM2—epilepsy syndrome	0.267	0.449	CbGaD
Flavoxate—PDE8B—forelimb—epilepsy syndrome	0.00961	0.112	CbGeAlD
Flavoxate—PDE8B—ganglion—epilepsy syndrome	0.00519	0.0604	CbGeAlD
Flavoxate—PDE4C—ganglion—epilepsy syndrome	0.00481	0.0559	CbGeAlD
Flavoxate—PDE4C—tongue—epilepsy syndrome	0.00476	0.0553	CbGeAlD
Flavoxate—PDE8B—forebrain—epilepsy syndrome	0.00218	0.0253	CbGeAlD
Flavoxate—PDE4C—brainstem—epilepsy syndrome	0.00209	0.0243	CbGeAlD
Flavoxate—PDE4C—forebrain—epilepsy syndrome	0.00202	0.0235	CbGeAlD
Flavoxate—PDE8B—telencephalon—epilepsy syndrome	0.002	0.0233	CbGeAlD
Flavoxate—PDE4C—telencephalon—epilepsy syndrome	0.00186	0.0216	CbGeAlD
Flavoxate—PDE8A—telencephalon—epilepsy syndrome	0.0018	0.021	CbGeAlD
Flavoxate—PDE7A—head—epilepsy syndrome	0.00179	0.0208	CbGeAlD
Flavoxate—PDE7A—nervous system—epilepsy syndrome	0.0017	0.0198	CbGeAlD
Flavoxate—PDE7A—central nervous system—epilepsy syndrome	0.00164	0.019	CbGeAlD
Flavoxate—PDE4D—telencephalon—epilepsy syndrome	0.00163	0.019	CbGeAlD
Flavoxate—PDE7B—head—epilepsy syndrome	0.00157	0.0182	CbGeAlD
Flavoxate—PDE7B—nervous system—epilepsy syndrome	0.00149	0.0173	CbGeAlD
Flavoxate—PDE4A—telencephalon—epilepsy syndrome	0.00145	0.0168	CbGeAlD
Flavoxate—PDE8B—midbrain—epilepsy syndrome	0.00144	0.0167	CbGeAlD
Flavoxate—PDE7B—central nervous system—epilepsy syndrome	0.00143	0.0166	CbGeAlD
Flavoxate—PDE8A—medulla oblongata—epilepsy syndrome	0.00142	0.0165	CbGeAlD
Flavoxate—PDE4C—midbrain—epilepsy syndrome	0.00133	0.0155	CbGeAlD
Flavoxate—PDE7A—brain—epilepsy syndrome	0.0013	0.0151	CbGeAlD
Flavoxate—PDE8A—midbrain—epilepsy syndrome	0.00129	0.0151	CbGeAlD
Flavoxate—PDE8A—spinal cord—epilepsy syndrome	0.00126	0.0147	CbGeAlD
Flavoxate—PDE8B—head—epilepsy syndrome	0.00125	0.0145	CbGeAlD
Flavoxate—PDE8B—nervous system—epilepsy syndrome	0.00118	0.0138	CbGeAlD
Flavoxate—PDE4C—head—epilepsy syndrome	0.00116	0.0134	CbGeAlD
Flavoxate—PDE8B—central nervous system—epilepsy syndrome	0.00114	0.0132	CbGeAlD
Flavoxate—PDE7B—brain—epilepsy syndrome	0.00114	0.0132	CbGeAlD
Flavoxate—PDE8B—cerebellum—epilepsy syndrome	0.00111	0.0129	CbGeAlD
Flavoxate—PDE4C—nervous system—epilepsy syndrome	0.0011	0.0127	CbGeAlD
Flavoxate—PDE4C—central nervous system—epilepsy syndrome	0.00105	0.0123	CbGeAlD
Flavoxate—PDE8A—cerebellum—epilepsy syndrome	0.001	0.0116	CbGeAlD
Flavoxate—PDE4B—forebrain—epilepsy syndrome	0.000937	0.0109	CbGeAlD
Flavoxate—CHRM2—forebrain—epilepsy syndrome	0.000931	0.0108	CbGeAlD
Flavoxate—PDE4D—cerebellum—epilepsy syndrome	0.000907	0.0106	CbGeAlD
Flavoxate—PDE8B—brain—epilepsy syndrome	0.000904	0.0105	CbGeAlD
Flavoxate—PDE4B—telencephalon—epilepsy syndrome	0.000862	0.01	CbGeAlD
Flavoxate—CHRM2—telencephalon—epilepsy syndrome	0.000856	0.00995	CbGeAlD
Flavoxate—CHRM1—forebrain—epilepsy syndrome	0.000847	0.00985	CbGeAlD
Flavoxate—PDE4C—brain—epilepsy syndrome	0.000837	0.00974	CbGeAlD
Flavoxate—Diphenidol—CHRM3—epilepsy syndrome	0.000828	0.293	CrCbGaD
Flavoxate—PDE8A—brain—epilepsy syndrome	0.000813	0.00946	CbGeAlD
Flavoxate—PDE4A—cerebellum—epilepsy syndrome	0.000803	0.00934	CbGeAlD
Flavoxate—CHRM1—telencephalon—epilepsy syndrome	0.000779	0.00906	CbGeAlD
Flavoxate—Diphenidol—CHRM1—epilepsy syndrome	0.000773	0.273	CrCbGaD
Flavoxate—PDE4D—brain—epilepsy syndrome	0.000737	0.00857	CbGeAlD
Flavoxate—PDE4B—medulla oblongata—epilepsy syndrome	0.000677	0.00787	CbGeAlD
Flavoxate—PDE4A—brain—epilepsy syndrome	0.000652	0.00758	CbGeAlD
Flavoxate—Diphenidol—CHRM2—epilepsy syndrome	0.000631	0.223	CrCbGaD
Flavoxate—PDE4B—midbrain—epilepsy syndrome	0.000619	0.0072	CbGeAlD
Flavoxate—PDE4B—spinal cord—epilepsy syndrome	0.000604	0.00702	CbGeAlD
Flavoxate—Antrafenine—PTGS2—epilepsy syndrome	0.000599	0.212	CrCbGaD
Flavoxate—Nervousness—Zonisamide—epilepsy syndrome	0.000545	0.00314	CcSEcCtD
Flavoxate—Confusional state—Propofol—epilepsy syndrome	0.000544	0.00314	CcSEcCtD
Flavoxate—Vertigo—Vigabatrin—epilepsy syndrome	0.00054	0.00312	CcSEcCtD
Flavoxate—Dry mouth—Midazolam—epilepsy syndrome	0.000539	0.00311	CcSEcCtD
Flavoxate—Feeling abnormal—Clobazam—epilepsy syndrome	0.000538	0.0031	CcSEcCtD
Flavoxate—PDE4B—head—epilepsy syndrome	0.000537	0.00624	CbGeAlD
Flavoxate—Urticaria—Lacosamide—epilepsy syndrome	0.000534	0.00308	CcSEcCtD
Flavoxate—CHRM2—head—epilepsy syndrome	0.000533	0.0062	CbGeAlD
Flavoxate—Confusional state—Midazolam—epilepsy syndrome	0.000533	0.00307	CcSEcCtD
Flavoxate—Vertigo—Diazepam—epilepsy syndrome	0.000532	0.00307	CcSEcCtD
Flavoxate—Tension—Clonazepam—epilepsy syndrome	0.00053	0.00306	CcSEcCtD
Flavoxate—Leukopenia—Diazepam—epilepsy syndrome	0.00053	0.00306	CcSEcCtD
Flavoxate—Tachycardia—Propofol—epilepsy syndrome	0.000527	0.00304	CcSEcCtD
Flavoxate—Tension—Phenytoin—epilepsy syndrome	0.000527	0.00304	CcSEcCtD
Flavoxate—Confusional state—Levetiracetam—epilepsy syndrome	0.000526	0.00303	CcSEcCtD
Flavoxate—Nervousness—Clonazepam—epilepsy syndrome	0.000525	0.00303	CcSEcCtD
Flavoxate—Tension—Oxcarbazepine—epilepsy syndrome	0.000524	0.00302	CcSEcCtD
Flavoxate—Vomiting—Trimethadione—epilepsy syndrome	0.000524	0.00302	CcSEcCtD
Flavoxate—Palpitations—Diazepam—epilepsy syndrome	0.000523	0.00302	CcSEcCtD
Flavoxate—Nervousness—Phenytoin—epilepsy syndrome	0.000522	0.00301	CcSEcCtD
Flavoxate—Nervousness—Oxcarbazepine—epilepsy syndrome	0.000519	0.00299	CcSEcCtD
Flavoxate—Urticaria—Clobazam—epilepsy syndrome	0.000518	0.00299	CcSEcCtD
Flavoxate—Somnolence—Acetazolamide—epilepsy syndrome	0.000517	0.00298	CcSEcCtD
Flavoxate—Headache—Trimethadione—epilepsy syndrome	0.000516	0.00298	CcSEcCtD
Flavoxate—Tachycardia—Midazolam—epilepsy syndrome	0.000516	0.00297	CcSEcCtD
Flavoxate—Dry mouth—Fosphenytoin—epilepsy syndrome	0.000514	0.00296	CcSEcCtD
Flavoxate—Skin disorder—Midazolam—epilepsy syndrome	0.000513	0.00296	CcSEcCtD
Flavoxate—Leukopenia—Felbamate—epilepsy syndrome	0.000513	0.00296	CcSEcCtD
Flavoxate—Vision blurred—Clonazepam—epilepsy syndrome	0.000509	0.00294	CcSEcCtD
Flavoxate—PDE4B—nervous system—epilepsy syndrome	0.000509	0.00592	CbGeAlD
Flavoxate—Confusional state—Fosphenytoin—epilepsy syndrome	0.000508	0.00293	CcSEcCtD
Flavoxate—Skin disorder—Levetiracetam—epilepsy syndrome	0.000507	0.00292	CcSEcCtD
Flavoxate—Palpitations—Felbamate—epilepsy syndrome	0.000506	0.00292	CcSEcCtD
Flavoxate—Eosinophilia—Pregabalin—epilepsy syndrome	0.000506	0.00292	CcSEcCtD
Flavoxate—CHRM2—nervous system—epilepsy syndrome	0.000505	0.00588	CbGeAlD
Flavoxate—Vertigo—Zonisamide—epilepsy syndrome	0.000504	0.00291	CcSEcCtD
Flavoxate—Drowsiness—Valproic Acid—epilepsy syndrome	0.000504	0.00291	CcSEcCtD
Flavoxate—Vision blurred—Oxcarbazepine—epilepsy syndrome	0.000503	0.0029	CcSEcCtD
Flavoxate—Tension—Carbamazepine—epilepsy syndrome	0.000503	0.0029	CcSEcCtD
Flavoxate—Leukopenia—Zonisamide—epilepsy syndrome	0.000502	0.0029	CcSEcCtD
Flavoxate—Nervousness—Carbamazepine—epilepsy syndrome	0.000498	0.00287	CcSEcCtD
Flavoxate—Palpitations—Zonisamide—epilepsy syndrome	0.000496	0.00286	CcSEcCtD
Flavoxate—Confusional state—Vigabatrin—epilepsy syndrome	0.000495	0.00285	CcSEcCtD
Flavoxate—Dry mouth—Diazepam—epilepsy syndrome	0.000493	0.00284	CcSEcCtD
Flavoxate—Tachycardia—Fosphenytoin—epilepsy syndrome	0.000491	0.00283	CcSEcCtD
Flavoxate—PDE4B—central nervous system—epilepsy syndrome	0.00049	0.0057	CbGeAlD
Flavoxate—Nausea—Trimethadione—epilepsy syndrome	0.000489	0.00282	CcSEcCtD
Flavoxate—Confusional state—Diazepam—epilepsy syndrome	0.000487	0.00281	CcSEcCtD
Flavoxate—CHRM2—central nervous system—epilepsy syndrome	0.000486	0.00566	CbGeAlD
Flavoxate—Tension—Lamotrigine—epilepsy syndrome	0.000486	0.0028	CcSEcCtD
Flavoxate—Vertigo—Clonazepam—epilepsy syndrome	0.000486	0.0028	CcSEcCtD
Flavoxate—CHRM1—head—epilepsy syndrome	0.000485	0.00564	CbGeAlD
Flavoxate—Leukopenia—Clonazepam—epilepsy syndrome	0.000484	0.00279	CcSEcCtD
Flavoxate—Vision blurred—Carbamazepine—epilepsy syndrome	0.000483	0.00279	CcSEcCtD
Flavoxate—Vertigo—Phenytoin—epilepsy syndrome	0.000482	0.00278	CcSEcCtD
Flavoxate—Nervousness—Lamotrigine—epilepsy syndrome	0.000481	0.00278	CcSEcCtD
Flavoxate—Leukopenia—Phenytoin—epilepsy syndrome	0.000481	0.00277	CcSEcCtD
Flavoxate—Somnolence—Propofol—epilepsy syndrome	0.00048	0.00277	CcSEcCtD
Flavoxate—Vertigo—Oxcarbazepine—epilepsy syndrome	0.00048	0.00277	CcSEcCtD
Flavoxate—Feeling abnormal—Acetazolamide—epilepsy syndrome	0.000479	0.00276	CcSEcCtD
Flavoxate—PDE4B—cerebellum—epilepsy syndrome	0.000479	0.00557	CbGeAlD
Flavoxate—Leukopenia—Oxcarbazepine—epilepsy syndrome	0.000478	0.00276	CcSEcCtD
Flavoxate—Palpitations—Clonazepam—epilepsy syndrome	0.000478	0.00276	CcSEcCtD
Flavoxate—Dry mouth—Felbamate—epilepsy syndrome	0.000477	0.00275	CcSEcCtD
Flavoxate—Skin disorder—Vigabatrin—epilepsy syndrome	0.000477	0.00275	CcSEcCtD
Flavoxate—Palpitations—Phenytoin—epilepsy syndrome	0.000475	0.00274	CcSEcCtD
Flavoxate—Palpitations—Oxcarbazepine—epilepsy syndrome	0.000472	0.00272	CcSEcCtD
Flavoxate—Tachycardia—Diazepam—epilepsy syndrome	0.000472	0.00272	CcSEcCtD
Flavoxate—Confusional state—Felbamate—epilepsy syndrome	0.000472	0.00272	CcSEcCtD
Flavoxate—Somnolence—Midazolam—epilepsy syndrome	0.00047	0.00271	CcSEcCtD
Flavoxate—Skin disorder—Diazepam—epilepsy syndrome	0.000469	0.00271	CcSEcCtD
Flavoxate—Dry mouth—Zonisamide—epilepsy syndrome	0.000467	0.00269	CcSEcCtD
Flavoxate—Vision blurred—Lamotrigine—epilepsy syndrome	0.000467	0.00269	CcSEcCtD
Flavoxate—Somnolence—Levetiracetam—epilepsy syndrome	0.000464	0.00268	CcSEcCtD
Flavoxate—Eosinophilia—Gabapentin—epilepsy syndrome	0.000464	0.00267	CcSEcCtD
Flavoxate—Vomiting—Phenobarbital—epilepsy syndrome	0.000464	0.00267	CcSEcCtD
Flavoxate—Urticaria—Acetazolamide—epilepsy syndrome	0.000462	0.00266	CcSEcCtD
Flavoxate—Confusional state—Zonisamide—epilepsy syndrome	0.000462	0.00266	CcSEcCtD
Flavoxate—Vertigo—Carbamazepine—epilepsy syndrome	0.000461	0.00266	CcSEcCtD
Flavoxate—CHRM1—nervous system—epilepsy syndrome	0.00046	0.00535	CbGeAlD
Flavoxate—Leukopenia—Carbamazepine—epilepsy syndrome	0.000459	0.00265	CcSEcCtD
Flavoxate—Headache—Phenobarbital—epilepsy syndrome	0.000457	0.00264	CcSEcCtD
Flavoxate—Tachycardia—Felbamate—epilepsy syndrome	0.000456	0.00263	CcSEcCtD
Flavoxate—Vomiting—Rufinamide—epilepsy syndrome	0.000455	0.00263	CcSEcCtD
Flavoxate—Dry mouth—Clonazepam—epilepsy syndrome	0.00045	0.0026	CcSEcCtD
Flavoxate—Headache—Rufinamide—epilepsy syndrome	0.000448	0.00259	CcSEcCtD
Flavoxate—Somnolence—Fosphenytoin—epilepsy syndrome	0.000448	0.00258	CcSEcCtD
Flavoxate—Dry mouth—Phenytoin—epilepsy syndrome	0.000447	0.00258	CcSEcCtD
Flavoxate—Tachycardia—Zonisamide—epilepsy syndrome	0.000447	0.00258	CcSEcCtD
Flavoxate—Vertigo—Lamotrigine—epilepsy syndrome	0.000445	0.00257	CcSEcCtD
Flavoxate—Feeling abnormal—Propofol—epilepsy syndrome	0.000445	0.00257	CcSEcCtD
Flavoxate—Confusional state—Clonazepam—epilepsy syndrome	0.000445	0.00257	CcSEcCtD
Flavoxate—Dry mouth—Oxcarbazepine—epilepsy syndrome	0.000445	0.00257	CcSEcCtD
Flavoxate—Skin disorder—Zonisamide—epilepsy syndrome	0.000445	0.00256	CcSEcCtD
Flavoxate—Leukopenia—Lamotrigine—epilepsy syndrome	0.000443	0.00256	CcSEcCtD
Flavoxate—CHRM1—central nervous system—epilepsy syndrome	0.000443	0.00515	CbGeAlD
Flavoxate—Confusional state—Phenytoin—epilepsy syndrome	0.000442	0.00255	CcSEcCtD
Flavoxate—Confusional state—Oxcarbazepine—epilepsy syndrome	0.00044	0.00254	CcSEcCtD
Flavoxate—Palpitations—Lamotrigine—epilepsy syndrome	0.000438	0.00253	CcSEcCtD
Flavoxate—Somnolence—Vigabatrin—epilepsy syndrome	0.000436	0.00252	CcSEcCtD
Flavoxate—Feeling abnormal—Midazolam—epilepsy syndrome	0.000435	0.00251	CcSEcCtD
Flavoxate—Nausea—Phenobarbital—epilepsy syndrome	0.000433	0.0025	CcSEcCtD
Flavoxate—Tachycardia—Clonazepam—epilepsy syndrome	0.000431	0.00248	CcSEcCtD
Flavoxate—Feeling abnormal—Levetiracetam—epilepsy syndrome	0.00043	0.00248	CcSEcCtD
Flavoxate—Somnolence—Diazepam—epilepsy syndrome	0.00043	0.00248	CcSEcCtD
Flavoxate—Urticaria—Propofol—epilepsy syndrome	0.000429	0.00247	CcSEcCtD
Flavoxate—Skin disorder—Clonazepam—epilepsy syndrome	0.000429	0.00247	CcSEcCtD
Flavoxate—Tachycardia—Phenytoin—epilepsy syndrome	0.000428	0.00247	CcSEcCtD
Flavoxate—Vomiting—Lacosamide—epilepsy syndrome	0.000427	0.00246	CcSEcCtD
Flavoxate—Dry mouth—Carbamazepine—epilepsy syndrome	0.000427	0.00246	CcSEcCtD
Flavoxate—Tachycardia—Oxcarbazepine—epilepsy syndrome	0.000425	0.00245	CcSEcCtD
Flavoxate—Nausea—Rufinamide—epilepsy syndrome	0.000425	0.00245	CcSEcCtD
Flavoxate—Skin disorder—Oxcarbazepine—epilepsy syndrome	0.000423	0.00244	CcSEcCtD
Flavoxate—Confusional state—Carbamazepine—epilepsy syndrome	0.000422	0.00243	CcSEcCtD
Flavoxate—Headache—Lacosamide—epilepsy syndrome	0.000421	0.00243	CcSEcCtD
Flavoxate—Urticaria—Midazolam—epilepsy syndrome	0.00042	0.00242	CcSEcCtD
Flavoxate—Drowsiness—Gabapentin—epilepsy syndrome	0.000418	0.00241	CcSEcCtD
Flavoxate—Somnolence—Felbamate—epilepsy syndrome	0.000416	0.0024	CcSEcCtD
Flavoxate—Feeling abnormal—Fosphenytoin—epilepsy syndrome	0.000415	0.00239	CcSEcCtD
Flavoxate—Vomiting—Clobazam—epilepsy syndrome	0.000415	0.00239	CcSEcCtD
Flavoxate—Dry mouth—Lamotrigine—epilepsy syndrome	0.000412	0.00238	CcSEcCtD
Flavoxate—Headache—Clobazam—epilepsy syndrome	0.000409	0.00236	CcSEcCtD
Flavoxate—Tachycardia—Carbamazepine—epilepsy syndrome	0.000408	0.00236	CcSEcCtD
Flavoxate—Confusional state—Lamotrigine—epilepsy syndrome	0.000408	0.00235	CcSEcCtD
Flavoxate—Somnolence—Zonisamide—epilepsy syndrome	0.000407	0.00235	CcSEcCtD
Flavoxate—Skin disorder—Carbamazepine—epilepsy syndrome	0.000406	0.00234	CcSEcCtD
Flavoxate—Feeling abnormal—Vigabatrin—epilepsy syndrome	0.000404	0.00233	CcSEcCtD
Flavoxate—Urticaria—Fosphenytoin—epilepsy syndrome	0.0004	0.00231	CcSEcCtD
Flavoxate—Nausea—Lacosamide—epilepsy syndrome	0.000399	0.0023	CcSEcCtD
Flavoxate—Feeling abnormal—Diazepam—epilepsy syndrome	0.000398	0.0023	CcSEcCtD
Flavoxate—Tachycardia—Lamotrigine—epilepsy syndrome	0.000395	0.00228	CcSEcCtD
Flavoxate—Somnolence—Clonazepam—epilepsy syndrome	0.000392	0.00226	CcSEcCtD
Flavoxate—Eosinophilia—Topiramate—epilepsy syndrome	0.00039	0.00225	CcSEcCtD
Flavoxate—Urticaria—Vigabatrin—epilepsy syndrome	0.00039	0.00225	CcSEcCtD
Flavoxate—Somnolence—Phenytoin—epilepsy syndrome	0.00039	0.00225	CcSEcCtD
Flavoxate—PDE4B—brain—epilepsy syndrome	0.000389	0.00452	CbGeAlD
Flavoxate—Somnolence—Oxcarbazepine—epilepsy syndrome	0.000388	0.00224	CcSEcCtD
Flavoxate—Nausea—Clobazam—epilepsy syndrome	0.000387	0.00223	CcSEcCtD
Flavoxate—Tension—Valproic Acid—epilepsy syndrome	0.000386	0.00223	CcSEcCtD
Flavoxate—CHRM2—brain—epilepsy syndrome	0.000386	0.00449	CbGeAlD
Flavoxate—Feeling abnormal—Felbamate—epilepsy syndrome	0.000385	0.00222	CcSEcCtD
Flavoxate—Urticaria—Diazepam—epilepsy syndrome	0.000384	0.00221	CcSEcCtD
Flavoxate—Nervousness—Valproic Acid—epilepsy syndrome	0.000382	0.00221	CcSEcCtD
Flavoxate—Feeling abnormal—Zonisamide—epilepsy syndrome	0.000377	0.00218	CcSEcCtD
Flavoxate—Somnolence—Carbamazepine—epilepsy syndrome	0.000372	0.00215	CcSEcCtD
Flavoxate—Urticaria—Felbamate—epilepsy syndrome	0.000372	0.00214	CcSEcCtD
Flavoxate—Vision blurred—Valproic Acid—epilepsy syndrome	0.000371	0.00214	CcSEcCtD
Flavoxate—Vomiting—Acetazolamide—epilepsy syndrome	0.00037	0.00213	CcSEcCtD
Flavoxate—Headache—Acetazolamide—epilepsy syndrome	0.000364	0.0021	CcSEcCtD
Flavoxate—Urticaria—Zonisamide—epilepsy syndrome	0.000364	0.0021	CcSEcCtD
Flavoxate—Feeling abnormal—Clonazepam—epilepsy syndrome	0.000364	0.0021	CcSEcCtD
Flavoxate—Feeling abnormal—Phenytoin—epilepsy syndrome	0.000361	0.00208	CcSEcCtD
Flavoxate—Somnolence—Lamotrigine—epilepsy syndrome	0.000359	0.00207	CcSEcCtD
Flavoxate—Feeling abnormal—Oxcarbazepine—epilepsy syndrome	0.000359	0.00207	CcSEcCtD
Flavoxate—Vertigo—Valproic Acid—epilepsy syndrome	0.000354	0.00204	CcSEcCtD
Flavoxate—Leukopenia—Valproic Acid—epilepsy syndrome	0.000352	0.00203	CcSEcCtD
Flavoxate—CHRM1—brain—epilepsy syndrome	0.000352	0.00409	CbGeAlD
Flavoxate—Urticaria—Clonazepam—epilepsy syndrome	0.000351	0.00202	CcSEcCtD
Flavoxate—Tension—Pregabalin—epilepsy syndrome	0.000349	0.00201	CcSEcCtD
Flavoxate—Urticaria—Phenytoin—epilepsy syndrome	0.000348	0.00201	CcSEcCtD
Flavoxate—Palpitations—Valproic Acid—epilepsy syndrome	0.000348	0.00201	CcSEcCtD
Flavoxate—Urticaria—Oxcarbazepine—epilepsy syndrome	0.000346	0.002	CcSEcCtD
Flavoxate—Nervousness—Pregabalin—epilepsy syndrome	0.000346	0.00199	CcSEcCtD
Flavoxate—Nausea—Acetazolamide—epilepsy syndrome	0.000345	0.00199	CcSEcCtD
Flavoxate—Feeling abnormal—Carbamazepine—epilepsy syndrome	0.000345	0.00199	CcSEcCtD
Flavoxate—Vomiting—Propofol—epilepsy syndrome	0.000343	0.00198	CcSEcCtD
Flavoxate—Headache—Propofol—epilepsy syndrome	0.000338	0.00195	CcSEcCtD
Flavoxate—Vomiting—Midazolam—epilepsy syndrome	0.000336	0.00194	CcSEcCtD
Flavoxate—Vision blurred—Pregabalin—epilepsy syndrome	0.000335	0.00193	CcSEcCtD
Flavoxate—Feeling abnormal—Lamotrigine—epilepsy syndrome	0.000333	0.00192	CcSEcCtD
Flavoxate—Urticaria—Carbamazepine—epilepsy syndrome	0.000332	0.00192	CcSEcCtD
Flavoxate—Vomiting—Levetiracetam—epilepsy syndrome	0.000332	0.00191	CcSEcCtD
Flavoxate—Headache—Midazolam—epilepsy syndrome	0.000331	0.00191	CcSEcCtD
Flavoxate—Dry mouth—Valproic Acid—epilepsy syndrome	0.000328	0.00189	CcSEcCtD
Flavoxate—Headache—Levetiracetam—epilepsy syndrome	0.000327	0.00189	CcSEcCtD
Flavoxate—Confusional state—Valproic Acid—epilepsy syndrome	0.000324	0.00187	CcSEcCtD
Flavoxate—Urticaria—Lamotrigine—epilepsy syndrome	0.000321	0.00185	CcSEcCtD
Flavoxate—Nausea—Propofol—epilepsy syndrome	0.000321	0.00185	CcSEcCtD
Flavoxate—Tension—Gabapentin—epilepsy syndrome	0.00032	0.00185	CcSEcCtD
Flavoxate—Vomiting—Fosphenytoin—epilepsy syndrome	0.00032	0.00185	CcSEcCtD
Flavoxate—Vertigo—Pregabalin—epilepsy syndrome	0.00032	0.00184	CcSEcCtD
Flavoxate—Leukopenia—Pregabalin—epilepsy syndrome	0.000319	0.00184	CcSEcCtD
Flavoxate—Nervousness—Gabapentin—epilepsy syndrome	0.000317	0.00183	CcSEcCtD
Flavoxate—Headache—Fosphenytoin—epilepsy syndrome	0.000315	0.00182	CcSEcCtD
Flavoxate—Palpitations—Pregabalin—epilepsy syndrome	0.000314	0.00181	CcSEcCtD
Flavoxate—Nausea—Midazolam—epilepsy syndrome	0.000314	0.00181	CcSEcCtD
Flavoxate—Tachycardia—Valproic Acid—epilepsy syndrome	0.000314	0.00181	CcSEcCtD
Flavoxate—Vomiting—Vigabatrin—epilepsy syndrome	0.000312	0.0018	CcSEcCtD
Flavoxate—Skin disorder—Valproic Acid—epilepsy syndrome	0.000312	0.0018	CcSEcCtD
Flavoxate—Nausea—Levetiracetam—epilepsy syndrome	0.00031	0.00179	CcSEcCtD
Flavoxate—Vision blurred—Gabapentin—epilepsy syndrome	0.000308	0.00177	CcSEcCtD
Flavoxate—Headache—Vigabatrin—epilepsy syndrome	0.000307	0.00177	CcSEcCtD
Flavoxate—Vomiting—Diazepam—epilepsy syndrome	0.000307	0.00177	CcSEcCtD
Flavoxate—Headache—Diazepam—epilepsy syndrome	0.000303	0.00175	CcSEcCtD
Flavoxate—Nausea—Fosphenytoin—epilepsy syndrome	0.000299	0.00173	CcSEcCtD
Flavoxate—Vomiting—Felbamate—epilepsy syndrome	0.000297	0.00172	CcSEcCtD
Flavoxate—Dry mouth—Pregabalin—epilepsy syndrome	0.000296	0.00171	CcSEcCtD
Flavoxate—Vertigo—Gabapentin—epilepsy syndrome	0.000293	0.00169	CcSEcCtD
Flavoxate—Headache—Felbamate—epilepsy syndrome	0.000293	0.00169	CcSEcCtD
Flavoxate—Confusional state—Pregabalin—epilepsy syndrome	0.000293	0.00169	CcSEcCtD
Flavoxate—Leukopenia—Gabapentin—epilepsy syndrome	0.000292	0.00168	CcSEcCtD
Flavoxate—Nausea—Vigabatrin—epilepsy syndrome	0.000292	0.00168	CcSEcCtD
Flavoxate—Vomiting—Zonisamide—epilepsy syndrome	0.000291	0.00168	CcSEcCtD
Flavoxate—Palpitations—Gabapentin—epilepsy syndrome	0.000288	0.00166	CcSEcCtD
Flavoxate—Nausea—Diazepam—epilepsy syndrome	0.000287	0.00166	CcSEcCtD
Flavoxate—Headache—Zonisamide—epilepsy syndrome	0.000287	0.00165	CcSEcCtD
Flavoxate—Somnolence—Valproic Acid—epilepsy syndrome	0.000286	0.00165	CcSEcCtD
Flavoxate—Tachycardia—Pregabalin—epilepsy syndrome	0.000283	0.00164	CcSEcCtD
Flavoxate—Skin disorder—Pregabalin—epilepsy syndrome	0.000282	0.00163	CcSEcCtD
Flavoxate—Vomiting—Clonazepam—epilepsy syndrome	0.000281	0.00162	CcSEcCtD
Flavoxate—Vomiting—Phenytoin—epilepsy syndrome	0.000279	0.00161	CcSEcCtD
Flavoxate—Nausea—Felbamate—epilepsy syndrome	0.000278	0.0016	CcSEcCtD
Flavoxate—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000277	0.0016	CcSEcCtD
Flavoxate—Headache—Clonazepam—epilepsy syndrome	0.000276	0.00159	CcSEcCtD
Flavoxate—Headache—Phenytoin—epilepsy syndrome	0.000275	0.00158	CcSEcCtD
Flavoxate—Headache—Oxcarbazepine—epilepsy syndrome	0.000273	0.00158	CcSEcCtD
Flavoxate—Nausea—Zonisamide—epilepsy syndrome	0.000272	0.00157	CcSEcCtD
Flavoxate—Dry mouth—Gabapentin—epilepsy syndrome	0.000272	0.00157	CcSEcCtD
Flavoxate—Tension—Topiramate—epilepsy syndrome	0.000269	0.00155	CcSEcCtD
Flavoxate—Confusional state—Gabapentin—epilepsy syndrome	0.000269	0.00155	CcSEcCtD
Flavoxate—Nervousness—Topiramate—epilepsy syndrome	0.000267	0.00154	CcSEcCtD
Flavoxate—Vomiting—Carbamazepine—epilepsy syndrome	0.000266	0.00153	CcSEcCtD
Flavoxate—Feeling abnormal—Valproic Acid—epilepsy syndrome	0.000265	0.00153	CcSEcCtD
Flavoxate—Nausea—Clonazepam—epilepsy syndrome	0.000262	0.00151	CcSEcCtD
Flavoxate—Headache—Carbamazepine—epilepsy syndrome	0.000262	0.00151	CcSEcCtD
Flavoxate—Nausea—Phenytoin—epilepsy syndrome	0.00026	0.0015	CcSEcCtD
Flavoxate—Tachycardia—Gabapentin—epilepsy syndrome	0.00026	0.0015	CcSEcCtD
Flavoxate—Nausea—Oxcarbazepine—epilepsy syndrome	0.000259	0.00149	CcSEcCtD
Flavoxate—Vision blurred—Topiramate—epilepsy syndrome	0.000259	0.00149	CcSEcCtD
Flavoxate—Skin disorder—Gabapentin—epilepsy syndrome	0.000259	0.00149	CcSEcCtD
Flavoxate—Somnolence—Pregabalin—epilepsy syndrome	0.000258	0.00149	CcSEcCtD
Flavoxate—Vomiting—Lamotrigine—epilepsy syndrome	0.000257	0.00148	CcSEcCtD
Flavoxate—Urticaria—Valproic Acid—epilepsy syndrome	0.000255	0.00147	CcSEcCtD
Flavoxate—Headache—Lamotrigine—epilepsy syndrome	0.000253	0.00146	CcSEcCtD
Flavoxate—Nausea—Carbamazepine—epilepsy syndrome	0.000248	0.00143	CcSEcCtD
Flavoxate—Vertigo—Topiramate—epilepsy syndrome	0.000247	0.00142	CcSEcCtD
Flavoxate—Leukopenia—Topiramate—epilepsy syndrome	0.000246	0.00142	CcSEcCtD
Flavoxate—Palpitations—Topiramate—epilepsy syndrome	0.000243	0.0014	CcSEcCtD
Flavoxate—Nausea—Lamotrigine—epilepsy syndrome	0.00024	0.00139	CcSEcCtD
Flavoxate—Feeling abnormal—Pregabalin—epilepsy syndrome	0.000239	0.00138	CcSEcCtD
Flavoxate—Somnolence—Gabapentin—epilepsy syndrome	0.000237	0.00137	CcSEcCtD
Flavoxate—Urticaria—Pregabalin—epilepsy syndrome	0.000231	0.00133	CcSEcCtD
Flavoxate—Dry mouth—Topiramate—epilepsy syndrome	0.000229	0.00132	CcSEcCtD
Flavoxate—Confusional state—Topiramate—epilepsy syndrome	0.000226	0.0013	CcSEcCtD
Flavoxate—Feeling abnormal—Gabapentin—epilepsy syndrome	0.000219	0.00127	CcSEcCtD
Flavoxate—Tachycardia—Topiramate—epilepsy syndrome	0.000219	0.00126	CcSEcCtD
Flavoxate—Skin disorder—Topiramate—epilepsy syndrome	0.000218	0.00126	CcSEcCtD
Flavoxate—Urticaria—Gabapentin—epilepsy syndrome	0.000212	0.00122	CcSEcCtD
Flavoxate—Vomiting—Valproic Acid—epilepsy syndrome	0.000204	0.00118	CcSEcCtD
Flavoxate—Headache—Valproic Acid—epilepsy syndrome	0.000201	0.00116	CcSEcCtD
Flavoxate—Somnolence—Topiramate—epilepsy syndrome	0.000199	0.00115	CcSEcCtD
Flavoxate—Nausea—Valproic Acid—epilepsy syndrome	0.000191	0.0011	CcSEcCtD
Flavoxate—Vomiting—Pregabalin—epilepsy syndrome	0.000185	0.00107	CcSEcCtD
Flavoxate—Feeling abnormal—Topiramate—epilepsy syndrome	0.000185	0.00107	CcSEcCtD
Flavoxate—Headache—Pregabalin—epilepsy syndrome	0.000182	0.00105	CcSEcCtD
Flavoxate—Urticaria—Topiramate—epilepsy syndrome	0.000178	0.00103	CcSEcCtD
Flavoxate—Nausea—Pregabalin—epilepsy syndrome	0.000173	0.000995	CcSEcCtD
Flavoxate—Vomiting—Gabapentin—epilepsy syndrome	0.000169	0.000977	CcSEcCtD
Flavoxate—Headache—Gabapentin—epilepsy syndrome	0.000167	0.000962	CcSEcCtD
Flavoxate—Nausea—Gabapentin—epilepsy syndrome	0.000158	0.000913	CcSEcCtD
Flavoxate—Vomiting—Topiramate—epilepsy syndrome	0.000142	0.000822	CcSEcCtD
Flavoxate—Headache—Topiramate—epilepsy syndrome	0.00014	0.00081	CcSEcCtD
Flavoxate—Nausea—Topiramate—epilepsy syndrome	0.000133	0.000768	CcSEcCtD
Flavoxate—CHRM2—Signaling Pathways—CHRM1—epilepsy syndrome	1.12e-05	7.84e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PDYN—epilepsy syndrome	1.12e-05	7.84e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—POMC—epilepsy syndrome	1.12e-05	7.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HTR7—epilepsy syndrome	1.12e-05	7.8e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KDR—epilepsy syndrome	1.11e-05	7.77e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—SRC—epilepsy syndrome	1.11e-05	7.75e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TSC2—epilepsy syndrome	1.11e-05	7.72e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AGT—epilepsy syndrome	1.1e-05	7.71e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HTR7—epilepsy syndrome	1.1e-05	7.7e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCR5—epilepsy syndrome	1.1e-05	7.68e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCL2—epilepsy syndrome	1.1e-05	7.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HBEGF—epilepsy syndrome	1.08e-05	7.58e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—APOE—epilepsy syndrome	1.08e-05	7.55e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—VEGFA—epilepsy syndrome	1.08e-05	7.55e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HTR2A—epilepsy syndrome	1.08e-05	7.52e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PRKCB—epilepsy syndrome	1.07e-05	7.48e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HBEGF—epilepsy syndrome	1.07e-05	7.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CDC42—epilepsy syndrome	1.07e-05	7.47e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GFAP—epilepsy syndrome	1.07e-05	7.47e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GAL—epilepsy syndrome	1.07e-05	7.47e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6ST—epilepsy syndrome	1.07e-05	7.45e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT3—epilepsy syndrome	1.06e-05	7.44e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KDR—epilepsy syndrome	1.06e-05	7.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP2—epilepsy syndrome	1.06e-05	7.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CHRM3—epilepsy syndrome	1.06e-05	7.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GRM5—epilepsy syndrome	1.06e-05	7.39e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CDC42—epilepsy syndrome	1.06e-05	7.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GAL—epilepsy syndrome	1.06e-05	7.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GFAP—epilepsy syndrome	1.06e-05	7.37e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT3—epilepsy syndrome	1.05e-05	7.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CHRM3—epilepsy syndrome	1.04e-05	7.29e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP2—epilepsy syndrome	1.04e-05	7.29e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GRM5—epilepsy syndrome	1.04e-05	7.29e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AVP—epilepsy syndrome	1.04e-05	7.23e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TSC2—epilepsy syndrome	1.02e-05	7.14e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AVP—epilepsy syndrome	1.02e-05	7.14e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AGT—epilepsy syndrome	1.02e-05	7.13e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PRKCB—epilepsy syndrome	1.02e-05	7.12e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6ST—epilepsy syndrome	1.02e-05	7.09e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CX3CR1—epilepsy syndrome	1.01e-05	7.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CX3CR1—epilepsy syndrome	1e-05	6.99e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—APOE—epilepsy syndrome	1e-05	6.99e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CHRM2—epilepsy syndrome	9.95e-06	6.94e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—BDKRB1—epilepsy syndrome	9.95e-06	6.94e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CX3CL1—epilepsy syndrome	9.95e-06	6.94e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—FGF2—epilepsy syndrome	9.92e-06	6.92e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—BDKRB1—epilepsy syndrome	9.82e-06	6.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CX3CL1—epilepsy syndrome	9.82e-06	6.86e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KDR—epilepsy syndrome	9.81e-06	6.85e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—POMC—epilepsy syndrome	9.76e-06	6.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CDC42—epilepsy syndrome	9.72e-06	6.78e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GABBR1—epilepsy syndrome	9.67e-06	6.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CDC42—epilepsy syndrome	9.59e-06	6.7e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCL2—epilepsy syndrome	9.55e-06	6.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GABBR1—epilepsy syndrome	9.55e-06	6.67e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PRKCB—epilepsy syndrome	9.44e-06	6.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AVP—epilepsy syndrome	9.41e-06	6.57e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6ST—epilepsy syndrome	9.4e-06	6.56e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—POMC—epilepsy syndrome	9.29e-06	6.49e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AVP—epilepsy syndrome	9.29e-06	6.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HRH3—epilepsy syndrome	9.28e-06	6.48e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—RELA—epilepsy syndrome	9.21e-06	6.43e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HRH3—epilepsy syndrome	9.16e-06	6.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—OPRM1—epilepsy syndrome	9.13e-06	6.38e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL2—epilepsy syndrome	9.09e-06	6.35e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MTOR—epilepsy syndrome	9.03e-06	6.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—OPRM1—epilepsy syndrome	9.01e-06	6.29e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CCR5—epilepsy syndrome	8.81e-06	6.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CCR5—epilepsy syndrome	8.69e-06	6.07e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—FGF2—epilepsy syndrome	8.63e-06	6.03e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR3—epilepsy syndrome	8.62e-06	6.02e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—HTR2A—epilepsy syndrome	8.62e-06	6.02e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—POMC—epilepsy syndrome	8.6e-06	6e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR3—epilepsy syndrome	8.51e-06	5.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—HTR2A—epilepsy syndrome	8.51e-06	5.94e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL2—epilepsy syndrome	8.41e-06	5.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NPY—epilepsy syndrome	8.4e-06	5.87e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ATP2A2—epilepsy syndrome	8.4e-06	5.87e-05	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—AKT1—epilepsy syndrome	8.38e-06	5.85e-05	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—AKT1—epilepsy syndrome	8.32e-06	5.81e-05	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—AKT1—epilepsy syndrome	8.32e-06	5.81e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CASP3—epilepsy syndrome	8.3e-06	5.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ATP2A2—epilepsy syndrome	8.3e-06	5.79e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NPY—epilepsy syndrome	8.3e-06	5.79e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—FGF2—epilepsy syndrome	8.22e-06	5.74e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AGT—epilepsy syndrome	8.18e-06	5.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HSPB1—epilepsy syndrome	8.11e-06	5.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CRH—epilepsy syndrome	8.11e-06	5.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL2—epilepsy syndrome	8.11e-06	5.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL3—epilepsy syndrome	8.11e-06	5.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—OXT—epilepsy syndrome	8.11e-06	5.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AGT—epilepsy syndrome	8.07e-06	5.64e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—JUN—epilepsy syndrome	8.06e-06	5.63e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—RELA—epilepsy syndrome	8.01e-06	5.6e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HSPB1—epilepsy syndrome	8e-06	5.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL2—epilepsy syndrome	8e-06	5.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CRH—epilepsy syndrome	8e-06	5.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL3—epilepsy syndrome	8e-06	5.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—OXT—epilepsy syndrome	8e-06	5.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCR5—epilepsy syndrome	8e-06	5.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCR5—epilepsy syndrome	7.9e-06	5.51e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MTOR—epilepsy syndrome	7.86e-06	5.49e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MMP9—epilepsy syndrome	7.85e-06	5.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HTR2A—epilepsy syndrome	7.83e-06	5.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HTR2A—epilepsy syndrome	7.73e-06	5.4e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—RELA—epilepsy syndrome	7.63e-06	5.33e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—AKT1—epilepsy syndrome	7.61e-06	5.31e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—FGF2—epilepsy syndrome	7.6e-06	5.31e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PRKCB—epilepsy syndrome	7.56e-06	5.28e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TSC1—epilepsy syndrome	7.54e-06	5.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTK2B—epilepsy syndrome	7.54e-06	5.26e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MTOR—epilepsy syndrome	7.48e-06	5.22e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PRKCB—epilepsy syndrome	7.46e-06	5.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TSC1—epilepsy syndrome	7.44e-06	5.2e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTK2B—epilepsy syndrome	7.44e-06	5.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AGT—epilepsy syndrome	7.43e-06	5.19e-05	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—AKT1—epilepsy syndrome	7.42e-06	5.18e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR2—epilepsy syndrome	7.33e-06	5.12e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NTRK2—epilepsy syndrome	7.33e-06	5.12e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SST—epilepsy syndrome	7.33e-06	5.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AGT—epilepsy syndrome	7.33e-06	5.12e-05	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—AKT1—epilepsy syndrome	7.3e-06	5.09e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DUSP6—epilepsy syndrome	7.27e-06	5.07e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR2—epilepsy syndrome	7.24e-06	5.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SST—epilepsy syndrome	7.24e-06	5.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NTRK2—epilepsy syndrome	7.24e-06	5.05e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—SRC—epilepsy syndrome	7.23e-06	5.05e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CASP3—epilepsy syndrome	7.23e-06	5.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADRA2A—epilepsy syndrome	7.18e-06	5.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DUSP6—epilepsy syndrome	7.17e-06	5.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLAT—epilepsy syndrome	7.15e-06	4.99e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADRA2A—epilepsy syndrome	7.08e-06	4.95e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—RELA—epilepsy syndrome	7.06e-06	4.93e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLAT—epilepsy syndrome	7.05e-06	4.93e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—VEGFA—epilepsy syndrome	7.05e-06	4.92e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—JUN—epilepsy syndrome	7.02e-06	4.9e-05	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—epilepsy syndrome	6.94e-06	4.85e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MTOR—epilepsy syndrome	6.92e-06	4.83e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—epilepsy syndrome	6.9e-06	4.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL12—epilepsy syndrome	6.89e-06	4.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—BDKRB2—epilepsy syndrome	6.89e-06	4.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—POMC—epilepsy syndrome	6.88e-06	4.81e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CASP3—epilepsy syndrome	6.88e-06	4.8e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PRKCB—epilepsy syndrome	6.86e-06	4.79e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6ST—epilepsy syndrome	6.83e-06	4.77e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MMP9—epilepsy syndrome	6.83e-06	4.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—BDKRB2—epilepsy syndrome	6.8e-06	4.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL12—epilepsy syndrome	6.8e-06	4.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—POMC—epilepsy syndrome	6.79e-06	4.74e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PRKCB—epilepsy syndrome	6.77e-06	4.73e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—JUNB—epilepsy syndrome	6.77e-06	4.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CNR1—epilepsy syndrome	6.77e-06	4.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6ST—epilepsy syndrome	6.75e-06	4.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLCB1—epilepsy syndrome	6.74e-06	4.71e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—JUN—epilepsy syndrome	6.68e-06	4.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—JUNB—epilepsy syndrome	6.68e-06	4.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CNR1—epilepsy syndrome	6.68e-06	4.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLCB1—epilepsy syndrome	6.66e-06	4.65e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—epilepsy syndrome	6.62e-06	4.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR7—epilepsy syndrome	6.6e-06	4.61e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR7—epilepsy syndrome	6.52e-06	4.55e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MMP9—epilepsy syndrome	6.5e-06	4.54e-05	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—epilepsy syndrome	6.42e-06	4.49e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HBEGF—epilepsy syndrome	6.41e-06	4.48e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CASP3—epilepsy syndrome	6.37e-06	4.44e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HBEGF—epilepsy syndrome	6.33e-06	4.42e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—epilepsy syndrome	6.31e-06	4.4e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—SRC—epilepsy syndrome	6.3e-06	4.4e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT3—epilepsy syndrome	6.29e-06	4.39e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—POMC—epilepsy syndrome	6.25e-06	4.36e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT3—epilepsy syndrome	6.21e-06	4.34e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—JUN—epilepsy syndrome	6.18e-06	4.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—POMC—epilepsy syndrome	6.17e-06	4.31e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADAM10—epilepsy syndrome	6.14e-06	4.29e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—epilepsy syndrome	6.13e-06	4.28e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL2—epilepsy syndrome	6.12e-06	4.27e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADAM10—epilepsy syndrome	6.07e-06	4.24e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL2—epilepsy syndrome	6.04e-06	4.22e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—epilepsy syndrome	6.02e-06	4.2e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—SRC—epilepsy syndrome	5.99e-06	4.19e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—epilepsy syndrome	5.84e-06	4.08e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—epilepsy syndrome	5.83e-06	4.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—S100B—epilepsy syndrome	5.81e-06	4.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SOCS3—epilepsy syndrome	5.75e-06	4.02e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDC42—epilepsy syndrome	5.74e-06	4.01e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—S100B—epilepsy syndrome	5.74e-06	4e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SOCS3—epilepsy syndrome	5.68e-06	3.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDC42—epilepsy syndrome	5.67e-06	3.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AVP—epilepsy syndrome	5.56e-06	3.88e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SRC—epilepsy syndrome	5.55e-06	3.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AVP—epilepsy syndrome	5.49e-06	3.83e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—epilepsy syndrome	5.4e-06	3.77e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HES1—epilepsy syndrome	5.25e-06	3.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HES1—epilepsy syndrome	5.19e-06	3.62e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FYN—epilepsy syndrome	5.11e-06	3.57e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—H2AFX—epilepsy syndrome	5.09e-06	3.56e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MEF2C—epilepsy syndrome	5.08e-06	3.55e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FYN—epilepsy syndrome	5.04e-06	3.52e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—H2AFX—epilepsy syndrome	5.03e-06	3.51e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MEF2C—epilepsy syndrome	5.02e-06	3.5e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	4.91e-06	3.43e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NGF—epilepsy syndrome	4.86e-06	3.39e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—YWHAZ—epilepsy syndrome	4.85e-06	3.39e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NGF—epilepsy syndrome	4.79e-06	3.35e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR5—epilepsy syndrome	4.72e-06	3.3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR5—epilepsy syndrome	4.66e-06	3.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2A—epilepsy syndrome	4.62e-06	3.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2A—epilepsy syndrome	4.56e-06	3.19e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—epilepsy syndrome	4.5e-06	3.14e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TSC2—epilepsy syndrome	4.39e-06	3.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AGT—epilepsy syndrome	4.39e-06	3.06e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TSC2—epilepsy syndrome	4.34e-06	3.03e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AGT—epilepsy syndrome	4.33e-06	3.02e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOE—epilepsy syndrome	4.3e-06	3e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOE—epilepsy syndrome	4.24e-06	2.96e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KDR—epilepsy syndrome	4.21e-06	2.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KDR—epilepsy syndrome	4.16e-06	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRKCB—epilepsy syndrome	4.05e-06	2.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6ST—epilepsy syndrome	4.04e-06	2.82e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRKCB—epilepsy syndrome	4e-06	2.79e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6ST—epilepsy syndrome	3.99e-06	2.78e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—epilepsy syndrome	3.91e-06	2.73e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—epilepsy syndrome	3.72e-06	2.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—POMC—epilepsy syndrome	3.69e-06	2.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—POMC—epilepsy syndrome	3.65e-06	2.55e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL2—epilepsy syndrome	3.61e-06	2.52e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL2—epilepsy syndrome	3.57e-06	2.49e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—epilepsy syndrome	3.45e-06	2.41e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FGF2—epilepsy syndrome	3.27e-06	2.28e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FGF2—epilepsy syndrome	3.22e-06	2.25e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RELA—epilepsy syndrome	3.03e-06	2.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RELA—epilepsy syndrome	2.99e-06	2.09e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MTOR—epilepsy syndrome	2.97e-06	2.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MTOR—epilepsy syndrome	2.93e-06	2.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	2.76e-06	1.93e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP3—epilepsy syndrome	2.73e-06	1.91e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—epilepsy syndrome	2.72e-06	1.9e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP3—epilepsy syndrome	2.7e-06	1.88e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—JUN—epilepsy syndrome	2.66e-06	1.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—JUN—epilepsy syndrome	2.62e-06	1.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—epilepsy syndrome	2.58e-06	1.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—epilepsy syndrome	2.55e-06	1.78e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—epilepsy syndrome	2.51e-06	1.75e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—epilepsy syndrome	2.47e-06	1.73e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SRC—epilepsy syndrome	2.38e-06	1.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SRC—epilepsy syndrome	2.35e-06	1.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—epilepsy syndrome	2.32e-06	1.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—epilepsy syndrome	2.29e-06	1.6e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—epilepsy syndrome	1.48e-06	1.03e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—epilepsy syndrome	1.46e-06	1.02e-05	CbGpPWpGaD
